June Lu

Dr. Lu had over 20 years of industry experience in innovative drug research and development. She is an accomplished professional in scientific, translational and strategic analysis aspects of R&D projects and pipeline assets. Her special expertise is in multidisciplinary, collaborative leadership experiences in the biotech and pharmaceutical industry. Prior to BeyondSpring, she worked at Endocyte, which developed 177Lu-PSMA-617, now approved drug Pluvicto®, and at Advanced Accelerator Applications, a Novartis company, and Novartis Institute for Biomedical Research.
Dr. Lu has led cross-functional project teams to develop small molecule-based strategies for cancer (FolateImmune; bispecific CAR-T cell therapy) and autoimmunity (DHFR/mTOR inhibitors). In addition, she has spearheaded deep-dive scientific efforts in macrophage-targeting, drug resistance & IO (PD-1/CTLA-4) combinations, target ID/pre-validation and indication selections. She has authored about 30 peer-reviewed publications and is an inventor for multiple patents.
Dr. June Lu received her Ph.D. in chemistry (biochemistry division) from Purdue University and B.S. degree in analytical chemistry from Zhejiang University of Technology.